CW January 2004
Volume 13Issue Number 1 January 2004 ISSN 10593802 Treating Mild Anemia in Cancer PatientsThe current American Society of Hematology (ASH) and ASCO (American Society of Clinical Oncology) guidelines recommend epoetin treatment for moderate anemia patients with hemoglobin levels <10g/d. Epoetin alfa (Procrit, Ortho Biotech) is known to increase hemoglobin (Hb) levels and reduce transfusion requirements in patients with anemia.
Go to Previous Page Go to Next Page Source & Additional Reading The current American Society of Hematology (ASH) and ASCO (American Society of Clinical Oncology) guidelines. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW January 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
